Burden of dengue in children in eight endemic countries in Asia and Latin America: a secondary analysis of the DEN-301 trial

Information from the abstract

Abstract Data from the placebo arm of DEN-301, a phase 3 trial of the TAK-003 dengue vaccine, were evaluated in this secondary post hoc analysis to assess dengue burden. Participants were aged 4–16 years from Asia Pacific and Latin America. The primary endpoint was efficacy of TAK-003 against virologically confirmed dengue (VCD). Hospitalized VCD was a secondary endpoint. Active surveillance captured both hospitalized and non-hospitalized cases. Among 6,687 placebo participants (30,620.6 person-years (p-y)), 9,698 febrile illnesses (incidence rate (IR) 31.7 per 100 p-y) occurred; 5.8% ( n = 560) were dengue. Most were DENV-1 (41.1%) or DENV-2 (34.5%). Dengue incidence differed between Asia Pacific (IR 2.7 per 100 p-y) and Latin America (IR 1.2 per 100 p-y). A total of 19 participants had dengue haemorrhagic fever or severe dengue. Of the VCD cases, 25.4% (142/560) were hospitalized. Here we highlight geographic, age-specific and temporal differences in dengue disease, underscoring the need for adaptive public health strategies to effectively control the disease (ClinicalTrials.gov identifier: NCT02747927 ).

Why this record is monitored

This record has an Impact Signal of 80/100 based on recency, source, collaboration, and bibliographic signals. It prioritizes monitoring and is not a judgment of research quality.

Related topics: Mosquito-borne diseases and control · Viral Infections and Outbreaks Research · Parasitic Diseases Research and Treatment